

Japan's Daiichi Sankyo unveils five-year business plan focused on oncology innovation

May 11, 2026 | News

2.3 trillion yen in oncology revenue to be delivered by 2030 through the launch of 20 new indications



Japan-based Daiichi Sankyo has revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncology revenue by 2030 and be a global top five oncology company by 2035 as part of its larger 2035 Vision to be recognised as a “trusted healthcare innovator transforming the lives of people through science and technology.”

A core ambition of the Five-Year Business Plan is to establish Daiichi Sankyo as a global top five oncology company by 2035 as measured by more than three trillion yen in FY2030 revenue, an increase from 2.1 trillion yen in FY2025 revenue, demonstrating aggressive growth.

Operating profit of more than 600 billion yen is expected to be achieved by end of fiscal year 2030. Target earnings per share (EPS) is estimated to be more than 260 yen in FY2030 with an adjusted dividend on equity (DOE) of 10.0% or higher each year and progressive dividends. Operating profit is expected to reach one trillion yen in the early 2030s.

Daiichi Sankyo will maximise the value of its DXd antibody drug conjugate (ADC) portfolio and additional oncology pipeline through rapid market penetration of more than 20 new indications across five medicines by 2030, reaching more than 700,000 new patients annually by 2035.

During FY2026, there are five practice-changing launches planned across the DXd ADC portfolio in various countries/regions globally, including four new breast cancer indications for Enhertu® and Datroway® and the company's first-ever launch in small cell lung cancer with ifinatamab deruxtecan (I-DXd).

Daiichi Sankyo is further strengthening its R&D engine through a breakthrough generating technology (BGT) approach, a platform-based drug discovery model, designed to deliver innovative medicines to patients faster and with a higher probability of success.